AZOPT

LOE Approaching

brinzolamide

NDAOPHTHALMICSUSPENSION/DROPS
Approved
Apr 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Carbonic Anhydrase Inhibitors

Pharmacologic Class:

Carbonic Anhydrase Inhibitor

Clinical Trials (5)

NCT03896633Phase 1/2Completed

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Started Feb 2018
637 enrolled
GlaucomaOpen Angle or Ocular Hypertension
NCT03150160Phase 4Completed

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

Started Sep 2017
1 enrolled
Glaucoma
NCT02140060Phase 2Completed

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Started Jun 2014
327 enrolled
GlaucomaOcular Hypertension
NCT01514734Phase 4Terminated

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Started Mar 2012
NCT01722604Phase 3Completed

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Started Jan 2012
258 enrolled
GlaucomaOpen Angle or Ocular Hypertension